Total ReturnsTotal Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s
Returns Beta
Beta has not been calculated since enough price history is not available
News & Corporate ActionsNews
No Recent News for the Company
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
07-Aug-2026 | Source : BSENotice published by way of an advertisement in respect of 22nd Annual General Meeting (AGM) of the Company.
Intimation Of Record Date For Remote E-Voting
06-Aug-2026 | Source : BSEIntimation of Record Date for remote e-voting
Reg. 34 (1) Annual Report.
06-Aug-2026 | Source : BSESubmission of Annual Report of Goldline Pharmaceutical Limited for FY 2025-26.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Key FactorsQuality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
3.65
Debt to EBITDA (avg)
1.32
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.33
Tax Ratio
23.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.29%
ROCE (avg)
29.36%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
37
Price to Book Value
2.82
EV to EBIT
7.28
EV to EBITDA
7.03
EV to Capital Employed
2.14
EV to Sales
1.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
29.36%
ROE (Latest)
28.91%
Technicals key factors
Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
Mildly Bullish
OBV
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned ShareholdingShareholding Snapshot : May 2026
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Swapan Premprakash Khandelwal (39.85%)
Highest Public shareholder
Sumit Bilgaiyan (7.03%)
Individual Investors Holdings
Financial
Company CV
